Ning Feng 1/23/25 Ning Feng 1/23/25 AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology Read More Ning Feng 11/14/24 Ning Feng 11/14/24 Merck signs up to $3.3 billion cancer drug deal with China-based LaNova Read More Ning Feng 11/10/23 Ning Feng 11/10/23 Fierce Pharma Asia—AstraZeneca's GLP-1 play; Takeda's cancer drug approval; BioNTech's bispecific deal Read More Ning Feng 10/26/22 Ning Feng 10/26/22 HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers Read More Ning Feng 10/24/22 Ning Feng 10/24/22 C4XD and HitGen to collaborate in inflammation hit identification project Read More Ning Feng 10/11/22 Ning Feng 10/11/22 IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder Read More Ning Feng 9/29/22 Ning Feng 9/29/22 Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc Read More Ning Feng 9/27/22 Ning Feng 9/27/22 Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv) Read More Ning Feng 9/21/22 Ning Feng 9/21/22 Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China Read More Ning Feng 9/14/22 Ning Feng 9/14/22 METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi Read More
Ning Feng 1/23/25 Ning Feng 1/23/25 AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology Read More
Ning Feng 11/14/24 Ning Feng 11/14/24 Merck signs up to $3.3 billion cancer drug deal with China-based LaNova Read More
Ning Feng 11/10/23 Ning Feng 11/10/23 Fierce Pharma Asia—AstraZeneca's GLP-1 play; Takeda's cancer drug approval; BioNTech's bispecific deal Read More
Ning Feng 10/26/22 Ning Feng 10/26/22 HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers Read More
Ning Feng 10/24/22 Ning Feng 10/24/22 C4XD and HitGen to collaborate in inflammation hit identification project Read More
Ning Feng 10/11/22 Ning Feng 10/11/22 IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder Read More
Ning Feng 9/29/22 Ning Feng 9/29/22 Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc Read More
Ning Feng 9/27/22 Ning Feng 9/27/22 Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv) Read More
Ning Feng 9/21/22 Ning Feng 9/21/22 Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China Read More
Ning Feng 9/14/22 Ning Feng 9/14/22 METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi Read More
